| Date | Title | Description |
| 11.09.2024 | Viatris' Tender Offers: A Strategic Move in the Financial Landscape | In the world of finance, timing is everything. Viatris Inc., a global healthcare giant, recently made headlines with its announcement regarding cash tender offers for its outstanding senior notes. This strategic maneuver, aimed at optimizin... |
| 10.09.2024 | Viatris Announces Expiration and Results of Any and All Cash Tender Offers | PITTSBURGH, Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that the previously announced cash tender offers (the "Any and All Tender Offers" and each, an ... |
| 10.09.2024 | Viatris Announces the Pricing Terms of Pending Any and All Cash Tender Offers | PITTSBURGH, Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the pricing terms of the previously announced cash tender offers (the "Any and All Tender Offers&quo... |
| 04.09.2024 | Viatris Announces Cash Tender Offers for Certain Outstanding Notes | PITTSBURGH, Sept. 4, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that it and its subsidiaries, Mylan Inc. ("Mylan") and Utah Acquisition Sub Inc. ("Utah Acq... |
| 20.08.2024 | The AI Dilemma: Fortune 500 Companies Grapple with Opportunities and Threats | In the fast-paced world of technology, artificial intelligence (AI) stands as both a beacon of hope and a shadow of fear. A recent study reveals that over half of Fortune 500 companies view AI as a potential threat to their business. This m... |
| 19.08.2024 | Свыше половины американских компаний из списка Fortune 500 считают ИИ угрозой для своего бизнеса | Порядка 56% крупнейших американских компаний из списка Fortune 500 заявили, что искусственный интеллект потенциально угрожает их бизнесу, пишет Financial Times со ссылкой на исследование корпоративных документов платформы Arize AI. Эта рабо... |
| 08.08.2024 | Viatris Reports Second Quarter Financial Results for 2024 | PITTSBURGH, Aug. 8, 2024 /PRNewswire/ --
Strong Results Demonstrate Power of Company's Diversification, Execution and Growing Base Business
Total Revenues of $3.8 Billion and Operational Revenue Growth of ~2% on a Divestiture-Adjusted Basis... |
| 06.08.2024 | Viatris Announces Second Quarter 2024 Dividend | PITTSBURGH, Aug. 6, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on August 5, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's comm... |
| 04.07.2024 | Launch of Phase 3 clinical trial with Nefecon in Japan | Launch of Phase 3 clinical trial with Nefecon in Japan
Thu, Jul 04, 2024 08:30 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announces that its partner Viatris Pharmaceutical... |
| 03.07.2024 | Viatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture | Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth
PITTSBURGH, July 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a glob... |
| 03.06.2024 | Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors | PITTSBURGH, June 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D., has been appointed as the newest member ... |
| 16.05.2024 | Biocon Q4 FY24 profit declines 57% y-o-y to ₹135 cr | Bengaluru-based Biocon Ltd. reported a 56.7 per cent decline in consolidated profit to ₹135.5 crore in Q4 FY24 compared to ₹313.2 crore in Q4 FY23. Additionally, consolidated profit fell by 79.7 per cent quarter-on-quarter (q-o-q) from ₹660... |
| 16.05.2024 | Prevent Blindness Launches "It Started With an Eye Exam" Campaign to Encourage, Educate and Empower the Public to Make Vision and Eye Health a Part of Overall Health Care | Prevent Blindness launches "It Started WIth an Eye Exam" campaign to encourage consumers to share stories of how eye care, including eye exams, has made a positive impact on their lives.
New "It Started with an Eye Exam"... |
| 09.05.2024 | Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges | PITTSBURGH, May 9, 2024 /PRNewswire/ --
Reports Total Revenues of $3.66 Billion; U.S. GAAP Net Earnings of $113.9 Million; Adjusted EBITDA of $1.19 Billion; U.S. GAAP EPS of $0.09; Adjusted EPS of $0.67; U.S. GAAP Net Cash Provided by Opera... |
| 02.05.2024 | Viatris to Participate in the BofA Securities 2024 Health Care Conference | PITTSBURGH, May 2, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the BofA Securities 2024 Health Care Conference at the Encore Hotel in Las Vegas, Nevada on Tu... |
| 01.05.2024 | Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health | PITTSBURGH and LONDON, May 1, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, recently launched Unmind as part of its global wellbeing program, Elevate. Unmind is a leading provider of workplace mental health ... |
| 12.03.2024 | Opioid Use Disorder Market to Reach USD 6.15 Billion by 2030, Driven by Growing Focus on Addiction Treatment | Opioid Use Disorder (OUD) Market
Opioid Use Disorder Market Analysis, Industry Trends and Growth Outlook AUSTIN, TEXAS, UNITED STATES, March 12, 2024 /EINPresswire.com/ -- The global opioid use disorder market is experiencing significant gr... |
| 05.03.2024 | Business wind down and take off for listed Swiss startups |
Since its inception in 2012, ObsEva SA (SIX: OBSN) has focused on the development of novel therapies for women's health and pregnancy, with a program focused on improving in vitro fertilization success rates. Due to low cash reserves, the ... |
| 05.03.2024 | Strides Pharma receives USFDA approval for neurology medication Gabapentin | Strides Pharma Science Limited (Strides) has received approval of Gabapentin Tablets USP, in strengths of 600 mg and 800 mg, by the United States Food & Drug Administration (USFDA). This announcement is a step towards expanding Strides'... |
| 12.01.2024 | Mylan Pharmaceuticals Inc., a Viatris Company, Conducting Voluntary Recall of One Batch of Semglee® (insulin glargine injection), 100 units/mL (U-100), 3 mL Prefilled Pens, Due to the Potential for a ... | COMPANY ANNOUNCEMENT This recall has been completed and FDA has terminated this recall.
When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endors... |
| 23.01.2023 | Viatris Announces Donations Totaling $1 Million To Provide Aid Supporting Access to Healthcare, Food Security and Water Stewardship | PITTSBURGH, PA / ACCESSWIRE / January 23, 2023 / Viatris Inc. (NASDAQ:VTRS), a global healthcare company, announced it is donating a total of $1 million to aid in supporting access to healthcare, food security and water stewardship in commu... |
| 14.11.2022 | One company’s healthcare network is making a difference in the lives of millions | Ms Anindita Rungta never expected her daughter would need to take oral steroids but that was exactly what happened in 2012.
The family had been dealing with her daughter’s eczema since she was a baby but things took a dramatic turn that yea... |
| 22.08.2022 | Claire’s Place Foundation Rolls Out Award-Winning Glow Ride | “The glowing reviews of our Glow Ride from participants and media would make my daughter, Claire, so proud,” said Claire’s Place Foundation Executive Director Melissa Yeager.
LOS ANGELES (PRWEB) August 22, 2022
Claire’s Place Foundation, a ... |
| 12.04.2022 | Mylan Pharmaceuticals Inc., a Viatris Company, Conducting Voluntary Nationwide Recall of One Batch of Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), Due to the Potential for... | COMPANY ANNOUNCEMENT
When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company. Read Announcement View Product... |
| 20.01.2022 | Recall report: Missing label, microbial contamination leads to recall of two batches of two drugs | Mylan Pharmaceuticals has recalled a batch of Semglee insulin pens after they were released without labels, the FDA said.
A single batch of non-interchangeable injection, 100 units/ml, 3mL packaged in cartons of five pen... |
| 01.12.2021 | Viatris Wins Federal Circuit Court Appeal Upholding District Court Decision Invalidating Biogen's Tecfidera® Patent | PITTSBURGH, Dec. 1, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that the United States Court of Appeals for the Federal Circuit affirmed the June 2020 decision by the U.S. District Court for the Northern District of Wes... |
| 03.11.2021 | Viatris and Biocon Biologics Announce Prime Therapeutics Prefers First-Ever Interchangeable Insulin Biosimilar Semglee® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) I... | Nov. 3, 2021
Viatris Inc. and Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd., are proud to confirm that Prime Therapeutics, a leading pharmacy benefit manager (PBM) serving nearly 33 million members, will list Semglee® (insulin... |
| 09.08.2021 | Viatris Reports Strong Second Quarter Results | |
| 29.07.2021 | The FDA just broke the logjam on interchangeable biologics. Here’s what that decision means | The Food and Drug Administration’s decision on Wednesday to approve a long-acting insulin called Semglee (insulin glargine-yfgn) as the first interchangeable biologic licensed for the U.S. market represents a major step forward to greater c... |
| 28.07.2021 | Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes | |
| 15.05.2021 | The pandemic’s toll on mental health: Three shifts in mindset | By Anamaria Jorga, Senior Director, Psychiatry, Pain and Inflammation, U.S. Medical Affairs at Viatris
Over the last year, the Covid-19 pandemic has necessitated an increase in attention on mental health — an area that typically takes a bac... |
| 12.05.2021 | VIATRIS INC.
Viatris : Reports Strong First Quarter 2021 Financial Results, Reaffirms 2021 Guidance and Announces Inaugural Quarterly Dividend (Form 8-K) | Viatris Inc. Reports Strong First Quarter 2021 Financial Results, Reaffirms 2021 Guidance and Announces Inaugural Quarterly Dividend
PITTSBURGH - May 10, 2021:
•Reports First Quarter 2021 Financial Results - Total Revenue of $4.4 billion, U... |
| 08.03.2021 | Viatris Inc. and Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalation... | |
| 22.02.2021 | Viatris Inc. Announces 2021 Financial Guidance and Reaffirms Strategic and Financial Commitments | |
| 11.12.2020 | Viatris Inc. Announces Additional Details of Previously Disclosed Global Restructuring Initiative | |
| - | ₹1,445 cr to fund Matrix Pharma’s buyout of Viatris' API biz" data-reg="Kotak Alt invests ₹1,445 cr to fund Matrix Pharma’s buyout of Viatris' API biz">Kotak Alt invests ₹1,445 cr to... | ₹1,445 cr to fund Matrix Pharma’s buyout of Viatris' API biz" data-reg="Kotak Alt invests ₹1,445 cr to fund Matrix Pharma’s buyout of Viatris' API biz">Kotak Alt invests ₹1,445 cr to fund Matrix Pharma’s buyout of Viatris'... |
| - | Why biosimilars are key to driving access to critical treatment | Brought to you by Viatris
For diseases like diabetes and certain cancers, biologic medicines have revolutionized care for patients. But the complexities around delivering these medicines to patients have resulted in lengthy timelines and hi... |
| - | Here are the top 25 companies to work for in India, according to LinkedIn — and most of them are not in tech | LinkedIn has released its annual list of top companies in India to work for and “a vast majority” of them are in either financial services or banking.
According to the professional networking platform, 10 out of 25 companies are from that s... |
